GREENWICH LIFESCIENCES, INC. Disaggregation Of Income Statement Expense Caption Reimbursement From Another Entity Amount
GREENWICH LIFESCIENCES, INC. (GLSI) reported Disaggregation Of Income Statement Expense Caption Reimbursement From Another Entity Amount of $700.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DisaggregationOfIncomeStatementExpenseCaptionReimbursementFromAnotherEntityAmount · last filed 2026-08-11
- GREENWICH LIFESCIENCES, INC. disaggregation of income statement expense caption reimbursement from another entity amount for the quarter ending 2026-06-30 was $700.00K, a 40.00% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. disaggregation of income statement expense caption reimbursement from another entity amount for the quarter ending 2026-03-31 was $2.20M, a 214.29% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. disaggregation of income statement expense caption reimbursement from another entity amount for the quarter ending 2025-06-30 was $500.00K.
- GREENWICH LIFESCIENCES, INC. disaggregation of income statement expense caption reimbursement from another entity amount for the quarter ending 2025-03-31 was $700.00K.
| Period end | Disaggregation Of Income Statement Expense Caption Reimbursement From Another Entity Amount 3 month | Disaggregation Of Income Statement Expense Caption Reimbursement From Another Entity Amount 6 month |
|---|---|---|
| 2026-06-30 | $700.00K 10-Q · filed 2026-08-11 | $2.90M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $2.20M 10-Q · filed 2026-06-04 | |
| 2025-06-30 | $500.00K 10-Q · filed 2026-08-11 | $1.20M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $700.00K 10-Q · filed 2026-06-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |